Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,450 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Safety in Healthy Adults Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending-Dose Study of EDP 322 in Healthy Adult Volunteers

NCT00990145
View directory record Official record
Conditions
MRSA, SSTI
Interventions
EDP-322
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2009 · Synced Oct 23, 2026, 9:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Blood Concentrations of Two Formulations of REGN2222 in Healthy Subjects

NCT02828397
View directory record Official record
Conditions
Healthy Volunteers
Interventions
REGN2222
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Daytona Beach, Florida • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 23, 2026, 9:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008 Administered by Sprayer

NCT01354379
View directory record Official record
Conditions
Healthy Adult Volunteers
Interventions
NB-1008, Fluzone IN
Biological
Lead sponsor
NanoBio Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Oct 23, 2026, 9:04 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults

NCT06863142
View directory record Official record
Conditions
Influenza Prevention, Seasonal Influenza
Interventions
VRC-FLUMOS0116-00-VP, ALFQ
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 23, 2026, 9:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating Lu AG22515 in Healthy Adults

NCT05136053
View directory record Official record
Conditions
Healthy Participants
Interventions
Lu AG22515, Placebo, Immune System Activator
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
19 Years to 60 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Long Beach, California • Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 23, 2026, 9:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose, Repeated Dose, and Conditional Food Effect Study of PF-05221304 in Healthy Subjects

NCT02871037
View directory record Official record
Conditions
Normal Healthy
Interventions
PF-05221304, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 23, 2026, 9:04 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Multiple-Ascending-Dose Study to Evaluate the Safety of Propoxyphene Napsylate In Healthy Adult Subjects

NCT01133873
View directory record Official record
Conditions
Healthy
Interventions
Propoxyphene napsylate (XP20C), Placebo
Drug
Lead sponsor
Xanodyne Pharmaceuticals
Industry
Eligibility
18 Years to 49 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Oct 23, 2026, 9:04 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects

NCT00630331
View directory record Official record
Conditions
Influenza
Interventions
Cell culture-derived influenza vaccine, Egg-derived influenza virus vaccine, Placebo
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
18 Years to 49 Years
Enrollment
11,404 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
17
States / cities
Denver, Colorado • Pembroke Pines, Florida • South Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 23, 2026, 9:04 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

First Time in Human Study of Long Acting VH4524184 Formulations

NCT06310551
View directory record Official record
Conditions
HIV Infections
Interventions
Oral VH4524184, VH4524184 Formulation A SC, Placebo Formulation A SC, rHuPH20, VH4524184 Formulation B SC, Placebo Formulation B SC, VH4524184 Formulation A IM, Placebo Formulation A IM, VH4524184 Formulation B IM, Placebo Formulation B IM
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
372 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
3
States / cities
Lenexa, Kansas • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 23, 2026, 9:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

2-Part Multiple Ascending Dose Study for Safety and Pharmacokinetics in Healthy and Elderly Subjects

NCT01673451
View directory record Official record
Conditions
CNS
Interventions
E2006, Placebo comparator
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Culver City, California • Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 11, 2013 · Synced Oct 23, 2026, 9:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults

NCT02350751
View directory record Official record
Conditions
Influenza
Interventions
MEDI8852, Placebo
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2015 · Synced Oct 23, 2026, 9:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple-Dose Study to Assess the Safety, Tolerability, and Steady State Pharmacokinetics of APD791 in Healthy Volunteers

NCT00619931
View directory record Official record
Conditions
Healthy
Interventions
APD791
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
19 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 23, 2026, 9:04 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function

NCT07269301
View directory record Official record
Conditions
Hepatic Impairment, Healthy
Interventions
PF-07328948
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 74 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
Lake Forest, California • Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 23, 2026, 9:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Experimental Ebola Vaccine Trial

NCT00072605
View directory record Official record
Conditions
Hemorrhagic Fever, Ebola, Healthy
Interventions
VRC-EBODNA012-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 44 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 23, 2026, 9:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.

NCT06742853
View directory record Official record
Conditions
Dyslipidemia
Interventions
AZD0780, Ezetimibe, Rosuvastatin, Bempedoic Acid, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 23, 2026, 9:04 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy of Klotho and Follistatin Gene Therapy

NCT07285629
View directory record Official record
Conditions
Healthy Adults
Interventions
Follistatin and klotho gene therapy
Genetic
Lead sponsor
Minicircle
Industry
Eligibility
50 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 23, 2026, 9:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study of PH100 (Ecklonia Cava Phlorotannins)

NCT04335045
View directory record Official record
Conditions
Safety Issues
Interventions
Placebo, PH100 100mg, PH100 200mg, PH100 400mg, PH100 800mg, PH100 1200mg, PH100 1600mg
Drug
Lead sponsor
Phloronol Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Oct 23, 2026, 9:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season

NCT02473510
View directory record Official record
Conditions
Influenza, Healthy
Interventions
Trivalent Influenza Vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
South Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 23, 2026, 9:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PfSPZ Challenge in Healthy Malaria-Naïve Adults in the United States

NCT02773979
View directory record Official record
Conditions
Plasmodium Falciparum Infection
Interventions
Chloroquine, PfSPZ (NF54) Challenge, Placebo
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Oct 23, 2026, 9:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Escalation Study of ONO-9054 in Healthy Volunteers

NCT01508988
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
ONO-9054
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years to 64 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Oct 23, 2026, 9:04 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of TAK-951 in Healthy Adults

NCT06610279
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-951, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 23, 2026, 9:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza

NCT06179446
View directory record Official record
Conditions
Grippe, Influenza, Vaccines
Interventions
pdmFlu vaccine, Placebo, Licensed influenza vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 84 Years
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
New Haven, Connecticut • Hollywood, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 23, 2026, 9:04 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older

NCT06727058
View directory record Official record
Conditions
Influenza Immunization
Interventions
Pandemic flu H5 mRNA vaccine, Placebo
Biological · Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
14
States / cities
La Mesa, California • DeLand, Florida • Lakeland, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 23, 2026, 9:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Safety Study of ALRN-5281 in Healthy Subjects

NCT01775358
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
ALRN-5281 0.015 mg/kg, ALRN-5281 0.05 mg/kg, ALRN-5281 0.15 mg/kg, Placebo 0.015 mg/kg, Placebo 0.05mg/kg, Placebo 0.15mg/kg
Drug
Lead sponsor
Aileron Therapeutics, Inc.
Industry
Eligibility
20 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 23, 2026, 9:04 PM EDT